Open AccessPatient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): Initial Report of Findings, 2012–2018
Author(s) -
Colleen M. McCarthy,
Nilsa LoyoBerríos,
H. A. Al-Qureshi,
Erin Mullen,
Gayle M. Gordillo,
Andrea L. Pusic,
Binita S. Ashar,
Katie Sommers,
Mark W. Clemens
Publication year - 2019
Publication title -
plastic and reconstructive surgery/psef cd journals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.841
H-Index - 179
eISSN - 1076-5751
pISSN - 0032-1052
DOI - 10.1097/prs.0000000000005571
Subject(s) - anaplastic large cell lymphoma , medicine , breast implant , etiology , epidemiology , lymphoma , t cell lymphoma , surgery , pediatrics , dermatology , implant
In January of 2011, the US Food and Drug Administration released a safety communication regarding the potential association between breast implants and anaplastic large cell lymphoma (ALCL). In August of 2012, the American Society of Plastic Surgeons, The Plastic Surgery Foundation, and the Food and Drug Administration signed a cooperative research and development agreement to develop a patient registry entitled the "Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology" (PROFILE).